The Innovative Medicines Initiative (IMI) is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), a public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients.

The QuIC-ConCePT (Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy) project is an IMI funded project which aims to provide drug developers with tools, imaging biomarkers, that can show earlier and more accurately how patients’ tumors respond to drugs in cancer clinical trials.

The QuIC-ConCePT consortium has 14 academic, one SME (small – medium sized enterprises) and eight EFPIA partners and is coordinated by AstraZeneca and managed by the European Organisation for Research and Treatment of Cancer (EORTC).

Read more »


QuIC-ConCePT, Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy, is an Innovative Medicines Initiative (IMI) funded project designed to qualify imaging biomarkers of tumor cell proliferation, apoptosis, and necrosis.

A major goal is to enable drug developers to incorporate these imaging biomarkers in Phase I clinical trials of investigational therapies and be confident that the imaging biomarkers are technically valid, that a measured change in the imaging biomarkers faithfully reflects the desired change in the underlying tumor pathology, and that the imaging biomarkers can be readily deployed in multiple cancer centers in a robust, consistent, ethical, and cost-effective way acceptable to the patients who participate in clinical trials.

Read more »

Project management

Access the BaseCamp project management platform.

This link is only for participants in the QuIC-ConCePT project. If your organization is a participant in QuIC-ConCePT, your organization’s contact person can help you gain access to this site.

Read more »